Business Wire

CA-PATIENT-SAFETY-MVMT

12.5.2021 14:02:10 CEST | Business Wire | Press release

Share
Patient Safety Movement Foundation Names Five Individuals to Inaugural Healthcare Safety Fellowship Program

The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, has selected five individuals for its inaugural Patient Safety Movement Foundation Healthcare Safety Fellowship program. The 12-month, part-time program is focused on providing education and continued development of skills for future healthcare leaders – positioning these stand-out individuals to serve as regional and global leaders in patient safety improvement for years to come.

“We are excited to launch our fellowship program and provide an opportunity to unify and prepare future leaders in patient safety,” said David B. Mayer, MD, CEO of the Patient Safety Movement Foundation. “These individuals have already demonstrated a commitment to improving healthcare, and we look forward to helping them design an individualized education plan that furthers their efforts and collectively helps us in our goal to achieve zero preventable patient deaths by 2030.”

Each of the five fellows will receive guidance from PSMF in designing an actionable plan that is tailored to their background, goals and the specific health needs of their region. In addition, fellows will have opportunities to interact and collaborate with an international network of patient safety and quality mentors, as well as facilitate and lead clinical coaching efforts with hospitals and healthcare organizations across the globe.

This year’s cohort participants include:

  • Luis Ramón Torres Torija Arguelles, MD, MBA
    Dr. Luis Torres Torija Arguelles is a physician with a specialty in quality of clinical care from the Tecnológico de Monterrey in Mexico. He currently works as a quality and patient safety coordinator at Hospital Español in Mexico City, Mexico, where he is responsible for the management, design, evaluation, improvement and innovation of clinical care and patient safety processes, incorporating methodologies for continuous improvement and better communication. His efforts to implement all the Patient Safety Movement Foundation’s Actional Patient Safety Solutions have earned his hospital the 5-star Hospital recognition.

  • Carol Gunn, MD
    Dr. Carol Gunn attended medical school at UC Davis and completed her internal medicine residency in Portland, Ore., followed by an additional year of training in occupational and environmental medicine at the University of Colorado. In 2007, she opened an independent occupational medicine practice. She thrives on working with individuals and groups advocating for system solutions – whether it be for health, wellness or patient safety.

  • Samar Hassan, PH, MSQ, CPHQ, FISQua
    Samar Hassan holds a master’s degree in healthcare quality management and is a registered pharmacist and certified healthcare quality professional with the National Association for Healthcare Quality (NAHQ). In addition, Hassan has worked with the Health Care Accreditation Council (HCAC) in Jordan and the region’s quality improvement and patient safety institution since 2018, where she has been involved in the design, implementation and evaluation of standards for quality and patient safety across health and social care institutions. She has also participated and supported HCAC's advocacy and public awareness programs to synthesize professionals, the public and decision makers on adopting and implementing quality improvement approaches.

  • Elizabeth Namugaya Igaga, MD
    Dr. Elizabeth Namugaya Igaga attended Makerere University in Kampala, Uganda, for medical school, as well as her master’s degree in anesthesia and critical care. She is currently doing her clinical practice at the Uganda Heart Institute. Igaga’s interest in patient safety was sparked after multiple firsthand experiences during residency that resulted in near misses or catastrophic outcomes. Since then, she has been passionate about fostering and building a culture of safety in perioperative care in Uganda.

  • Ebikapaye Okoyen, MD, MBBS, MBA, MHPM, FISQua
    Dr. Ebikapaye Okoyen works in the Ministry of Health in Yenagoa, Nigeria, as the deputy director and state program manager for Saving One Million Lives Program for Results (SOML PforR) – a World Bank-funded, results-based program financing maternal and child health and nutrition aimed at improving quantity and quality of service. He is a fellow and member of several professional associations including the Nigerian Medical Association, the Society for Quality in Healthcare in Nigeria (SQHN) and is a certified SQHN Health Facility Surveyor with a specialist certificate on the Fundamentals of External Evaluation Surveying from the International Society for Quality in Healthcare (ISQua). He has also published papers in health services research.

To learn more about the Patient Safety Movement Foundation Healthcare Safety Fellowship, visit: https://patient.sm/PR-Fellowship .

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals, with more than three million deaths globally, as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero preventable patient harm and death. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye